ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock
July 11 2012 - 3:01PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN) announced today that it intends
to offer for sale its common stock in an underwritten public
offering. The offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering.
Morgan Stanley & Co. LLC and Jefferies & Company, Inc.
are acting as joint book-running managers for the proposed
offering.
The securities described above are being offered by ImmunoGen
pursuant to an automatically effective shelf registration statement
that was previously filed with the Securities and Exchange
Commission (SEC). This press release does not constitute an offer
to sell or a solicitation of an offer to buy the securities in this
offering, nor shall there be any sale of these securities in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.
A preliminary prospectus supplement related to the offering will be
filed with the SEC and will be available on the SEC’s website
located at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to this
offering may be obtained, when available, from Morgan Stanley &
Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor,
New York, NY 10014, by telephone at 866-718-1649, or by email at
prospectus@morganstanley.com and from Jefferies & Company,
Inc., Equity Syndicate Prospectus Department, 520 Madison Avenue,
12th Floor, New York, NY 10022, by telephone at 877-547-6340, or by
email at Prospectus_Department@Jefferies.com.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company’s expertise in tumor biology, monoclonal antibodies,
potent cancer-cell killing agents and engineered linkers. The
Company’s Targeted Antibody Payload (TAP) technology uses
monoclonal antibodies to deliver one of ImmunoGen’s proprietary
cancer-cell killing agents specifically to tumor cells. There are
now ten TAP compounds in clinical development, of which three are
wholly owned by ImmunoGen. ImmunoGen’s collaborative partners
include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche
and Sanofi. The most advanced compound using ImmunoGen’s TAP
technology, trastuzumab emtansine (T-DM1), is in Phase III testing
through the Company’s collaboration with Genentech, a member of the
Roche Group.
This press release includes forward-looking statements,
including statements related to the proposed public offering of
securities by ImmunoGen. For these statements, ImmunoGen claims the
protection of the safe harbor for forward-looking statements
provided by the Private Securities Litigation Reform Act of 1995.
It should be noted that there are risks and uncertainties related
to the public offering. A review of these risks can be found in
ImmunoGen’s Annual Report on Form 10-K for the fiscal year ended
June 30, 2011 and other reports filed with the Securities and
Exchange Commission. ImmunoGen undertakes no obligation to revise
or update any forward-looking statement to reflect events or
circumstances after the issuance of this press release.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Oct 2023 to Oct 2024